Do you have a transformative therapeutic or platform technology but need the support of the life science community as you take the next step? MassBioDrive can help you accelerate your early-stage biotech – all at no cost.
Learn more & apply by 7/1 https://t.co/iy2asWLPVd
Excited to join the Review Board for @MassBio’s new biotech accelerator, MassBioDrive. A unique and powerful resource for early-stage entrepreneurs that will provide opportunities to innovators from all parts of the ecosystem.
Learn more & apply by 2/4: https://t.co/8aOdJbvRFF
To celebrate Tom Krummel's retirement from Stanford, we gathered for an evening of #storytelling. Tom is continuing as a senior advisor for Biodesign and board chair @FogartyInnov so we're not sure this counts as retirement but we miss you already TK! #healthtech#innovation
We are so proud of Tariq Khalil for being a 2020-21 Light of Hope recipient. The Light of Hope Award is given to one student at every school who best demonstrates the attributes of Dr. King. Tariq, thank you for being a light of hope for those around you! #CardinalStrong
For his passion for teaching in all his classes - a 2020 Withrow Teaching Excellence Award in the College of Engineering goes to Hassan Khalil, professor of electrical and computer engineering. Find out more on this award-winning #MSU professor at: https://t.co/Q4t3GzondN
Whoa, 147 (36%) out of 408 people tested positive for the #coronavirus at a large homeless shelter in Boston
https://t.co/WsecQWxdDA
More interestingly, only ~1/6 showed symptoms among those tested positive, i.e. 1:5 for symptomatic vs asymptomatic. #COVID19
@ScottGottliebMD Ideally, we could also conduct a serology test on the ~85% who tested negative to see what percent of those patients previously had the virus. That would give us the true total exposure rate
@bradloncar Interesting but will still need the RCTs to have any sense of real efficacy. What has been observed mortality of ventilated patients in major hot spots? If ~50%, then could be some effect here. Need more data
A cohort of patients with severe Covid-19 received treatment with remdesivir under a compassionate-use protocol. Improvement in oxygen-support status was observed in 68% of patients, and overall mortality was 13% over a median follow-up of 26 days. #COVID19
@Farzad_MD How much can we really read into new case growth and positivity rate given lack of tests available? Especially with guidance in NYC to only test where it will change clinical management?